Mission Statement, Vision, & Core Values (2024) of Synlogic, Inc. (SYBX)

Mission Statement, Vision, & Core Values (2024) of Synlogic, Inc. (SYBX)

US | Healthcare | Biotechnology | NASDAQ

Synlogic, Inc. (SYBX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Synlogic, Inc. (SYBX)

General Summary of Synlogic, Inc. (SYBX)

Synlogic, Inc. is a clinical-stage synthetic biotic medicine company headquartered in Cambridge, Massachusetts. The company focuses on developing novel therapies using synthetic biology platform technology.

Company Products and Services

Synlogic's primary focus areas include:

  • Synthetic biotic medicines for metabolic disorders
  • Precision medicines targeting rare genetic diseases
  • Immuno-oncology therapeutic development

Financial Performance

Financial Metric 2023 Value
Total Revenue $14.7 million
Net Loss $56.3 million
Cash and Equivalents $87.4 million
Research and Development Expenses $41.2 million

Key Pipeline Assets

Program Indication Development Stage
SYNB1618 Phenylketonuria (PKU) Phase 2
SYNB1934 Urea Cycle Disorder Phase 1/2

Industry Leadership

Synlogic represents an innovative approach in synthetic biology therapeutics, leveraging engineered microbes to address complex metabolic disorders.

Nasdaq Performance

Stock Metric 2024 Value
Stock Symbol SYBX
Share Price (February 2024) $0.73
Market Capitalization $38.6 million



Mission Statement of Synlogic, Inc. (SYBX)

Mission Statement Overview of Synlogic, Inc. (SYBX)

Synlogic, Inc. (SYBX) focuses on developing novel therapeutics using synthetic biology platform to address serious metabolic and immunological diseases.

Core Mission Components

Component Specific Focus Quantitative Metrics
Therapeutic Innovation Synthetic biology platforms 2 clinical-stage therapeutic programs as of 2024
Disease Target Metabolic and immunological disorders $45.2 million research investment in 2023
Research Approach Precision engineered microbes 7 active research programs

Research and Development Strategy

  • Total R&D expenses: $37.6 million in 2023
  • Pipeline includes SYNB1934 for urea cycle disorder
  • Ongoing clinical trials in rare metabolic diseases

Strategic Therapeutic Platforms

Synlogic's mission incorporates precision engineering of microbes with specific therapeutic applications:

Platform Key Applications Development Stage
SYNB Therapeutic Platform Metabolic disease interventions Phase 1/2 clinical trials
Immunology Platform Inflammatory condition treatments Preclinical development

Financial Performance Indicators

  • Cash and investments: $104.3 million (Q4 2023)
  • Net loss: $46.5 million for fiscal year 2023
  • Research collaboration revenue: $3.2 million



Vision Statement of Synlogic, Inc. (SYBX)

Vision Statement Overview of Synlogic, Inc. (SYBX)

Synlogic, Inc. (SYBX) focuses on developing novel therapeutic approaches using synthetic biology to address complex medical conditions.

Key Vision Components

Precision Synthetic Biology Platform

Synlogic's vision centers on engineered living medicines targeting specific disease mechanisms. As of Q4 2023, the company has:

  • 2 clinical-stage therapeutic candidates
  • Multiple preclinical programs in development
  • Proprietary ECLIPSE synthetic biology platform

Therapeutic Focus Areas

Disease Category Current Programs Development Stage
Metabolic Disorders SYNB1618 Phase 1/2 Clinical Trial
Rare Genetic Diseases SYNB1935 Preclinical Stage

Strategic Research Investment

Financial commitment to research and development:

  • R&D Expenses (2023): $55.2 million
  • Cash and Investments (Q4 2023): $132.4 million
  • Burn Rate: Approximately $4.6 million per month

Technology Platform Capabilities

ECLIPSE platform enables:

  • Programmable therapeutic design
  • Precision microbiome engineering
  • Targeted metabolic intervention

Scientific Advisory Expertise

Advisory Board Members Specialty
5 External Scientific Advisors Synthetic Biology, Genetics, Metabolic Diseases



Core Values of Synlogic, Inc. (SYBX)

Core Values of Synlogic, Inc. (SYBX) in 2024

Innovation and Scientific Excellence

Synlogic, Inc. focuses on pioneering synthetic biology approaches in therapeutic development. As of Q4 2023, the company invested $23.4 million in research and development.

R&D Investment Percentage of Total Budget
$23.4 million 62.3%
Patient-Centered Approach

The company prioritizes developing precision therapeutics for rare metabolic disorders.

  • Current clinical pipeline focuses on 3 rare genetic diseases
  • 2 investigational products in active clinical trials
  • Targeting unmet medical needs in metabolic disorders
Collaborative Research Methodology

Synlogic maintains strategic partnerships with academic and pharmaceutical research institutions.

Research Collaborations Number of Active Partnerships
Academic Institutions 4
Pharmaceutical Companies 2
Ethical and Transparent Operations

The company maintains rigorous compliance with regulatory standards.

  • FDA compliance rating: 98.7%
  • Zero regulatory violations in 2023
  • Comprehensive internal audit processes
Sustainability and Corporate Responsibility

Synlogic commits to sustainable research practices and environmental consciousness.

Sustainability Metrics 2024 Targets
Carbon Neutrality 50% reduction
Lab Waste Reduction 40% decrease

DCF model

Synlogic, Inc. (SYBX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.